Mostly patients addressed the panel saying they wanted the process expedited. The director of a state marijuana advocacy program says among the concerns is the potential of the drug being too costly. Dan Linn with Illinois NORML says that could undermine the program.
"If the price of medicine through the program is ten percent or fifteen percent higher than the street value, we'll see a lot of non-compliance where patients registered to be in the program--they go to the dispensary, they look at the medicine--they might buy a little bit the first time. But if it's such a cost burden for them that they're not going to continue buying it through the program, they're going to continue going to the illegal market."
Other concerns raised at the hearing include security efforts like background checks, finger-printing and requiring established patient-doctor relationships. An attorney for the public health agency says any changes in those areas would need legislative approval.
The state has yet to hand out licenses for growing or selling medical marijuana.